CA2484626A1 - Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b - Google Patents
Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b Download PDFInfo
- Publication number
- CA2484626A1 CA2484626A1 CA002484626A CA2484626A CA2484626A1 CA 2484626 A1 CA2484626 A1 CA 2484626A1 CA 002484626 A CA002484626 A CA 002484626A CA 2484626 A CA2484626 A CA 2484626A CA 2484626 A1 CA2484626 A1 CA 2484626A1
- Authority
- CA
- Canada
- Prior art keywords
- formulation
- per
- alpha
- interferon
- alpha interferon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 160
- 238000000034 method Methods 0.000 title claims abstract description 60
- 238000012384 transportation and delivery Methods 0.000 title claims abstract description 29
- 102100040018 Interferon alpha-2 Human genes 0.000 title description 15
- 108010079944 Interferon-alpha2b Proteins 0.000 title description 15
- 230000002685 pulmonary effect Effects 0.000 title description 5
- 238000009472 formulation Methods 0.000 claims abstract description 154
- 239000000443 aerosol Substances 0.000 claims abstract description 47
- 210000004072 lung Anatomy 0.000 claims abstract description 23
- 102000014150 Interferons Human genes 0.000 claims abstract description 22
- 108010050904 Interferons Proteins 0.000 claims abstract description 22
- 229940079322 interferon Drugs 0.000 claims abstract description 20
- 241001465754 Metazoa Species 0.000 claims abstract description 13
- 239000013011 aqueous formulation Substances 0.000 claims abstract description 9
- 230000004071 biological effect Effects 0.000 claims abstract description 6
- 108010047761 Interferon-alpha Proteins 0.000 claims description 87
- 102000006992 Interferon-alpha Human genes 0.000 claims description 86
- 239000000243 solution Substances 0.000 claims description 61
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 37
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 37
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 37
- 229940068977 polysorbate 20 Drugs 0.000 claims description 33
- 239000002245 particle Substances 0.000 claims description 30
- 210000004369 blood Anatomy 0.000 claims description 21
- 239000008280 blood Substances 0.000 claims description 21
- 239000003381 stabilizer Substances 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 239000010419 fine particle Substances 0.000 claims description 17
- -1 poly(oxy-1,2-ethanediyl) Polymers 0.000 claims description 17
- 239000007853 buffer solution Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 claims description 11
- 238000011287 therapeutic dose Methods 0.000 claims description 7
- 230000003139 buffering effect Effects 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 239000008215 water for injection Substances 0.000 claims description 5
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 3
- 210000002345 respiratory system Anatomy 0.000 claims description 2
- 239000000126 substance Substances 0.000 abstract description 18
- 230000009885 systemic effect Effects 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 239000002552 dosage form Substances 0.000 description 28
- 238000012387 aerosolization Methods 0.000 description 22
- 239000008364 bulk solution Substances 0.000 description 21
- 230000008014 freezing Effects 0.000 description 19
- 238000007710 freezing Methods 0.000 description 19
- 239000000047 product Substances 0.000 description 18
- 229940079593 drug Drugs 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- 239000012528 membrane Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 238000010254 subcutaneous injection Methods 0.000 description 10
- 238000001125 extrusion Methods 0.000 description 9
- 230000003285 pharmacodynamic effect Effects 0.000 description 9
- 238000012545 processing Methods 0.000 description 9
- 239000007929 subcutaneous injection Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000004007 reversed phase HPLC Methods 0.000 description 8
- 108091006905 Human Serum Albumin Proteins 0.000 description 7
- 102000008100 Human Serum Albumin Human genes 0.000 description 7
- 230000003434 inspiratory effect Effects 0.000 description 7
- 229940065638 intron a Drugs 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 229960001484 edetic acid Drugs 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000004743 Polypropylene Substances 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 229920001155 polypropylene Polymers 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- YAJCHEVQCOHZDC-QMMNLEPNSA-N actrapid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@H](C)CC)[C@H](C)CC)[C@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(N)=O)C1=CNC=N1 YAJCHEVQCOHZDC-QMMNLEPNSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 244000309464 bull Species 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 150000002978 peroxides Chemical class 0.000 description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 description 4
- 238000010257 thawing Methods 0.000 description 4
- 230000002411 adverse Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 108010078049 Interferon alpha-2 Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013628 high molecular weight specie Substances 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 229960003507 interferon alfa-2b Drugs 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000013627 low molecular weight specie Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000002663 nebulization Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 238000012385 systemic delivery Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 1
- 244000037640 animal pathogen Species 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/159,083 | 2002-05-31 | ||
| US10/159,083 US6830744B2 (en) | 2002-05-31 | 2002-05-31 | Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b |
| PCT/US2003/010832 WO2003102014A2 (en) | 2002-05-31 | 2003-04-08 | Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2484626A1 true CA2484626A1 (en) | 2003-12-11 |
Family
ID=29582814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002484626A Abandoned CA2484626A1 (en) | 2002-05-31 | 2003-04-08 | Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6830744B2 (enExample) |
| EP (1) | EP1515744A4 (enExample) |
| JP (1) | JP2005531604A (enExample) |
| AU (1) | AU2003221700A1 (enExample) |
| CA (1) | CA2484626A1 (enExample) |
| WO (1) | WO2003102014A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10134650B4 (de) * | 2001-07-20 | 2009-12-03 | Roche Diagnostics Gmbh | System zur Entnahme kleiner Körperflüssigkeitsmengen |
| US20050232899A1 (en) * | 2002-05-31 | 2005-10-20 | Aradigm Corporation | Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b |
| ITMI20032067A1 (it) * | 2003-10-23 | 2005-04-24 | Unihart Corp | Formulazione spray per il trattamento delle infezioni virali. |
| JP5041550B2 (ja) * | 2006-08-01 | 2012-10-03 | 日本たばこ産業株式会社 | エアロゾル吸引器 |
| JP5675995B2 (ja) * | 2010-09-24 | 2015-02-25 | イーティス，ドノヴァン，ビー． | 小型、低流抵抗エアロゾル発生器及び同様の操作方法 |
| CN105310988B (zh) * | 2015-11-23 | 2018-05-04 | 哈药集团生物工程有限公司 | 一种含有重组人干扰素α2b的冻干药物组合物 |
| CN113491807B (zh) * | 2020-04-03 | 2023-07-28 | 深圳麦克韦尔科技有限公司 | 一种气溶胶产生装置 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0082481B2 (en) | 1981-12-23 | 1990-09-12 | Schering Corporation | Stabilised alpha-interferon formulations and their preparation |
| JPH05963A (ja) * | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
| US5558085A (en) | 1993-01-29 | 1996-09-24 | Aradigm Corporation | Intrapulmonary delivery of peptide drugs |
| US5743250A (en) | 1993-01-29 | 1998-04-28 | Aradigm Corporation | Insulin delivery enhanced by coached breathing |
| US5709202A (en) | 1993-05-21 | 1998-01-20 | Aradigm Corporation | Intrapulmonary delivery of aerosolized formulations |
| US5509404A (en) | 1994-07-11 | 1996-04-23 | Aradigm Corporation | Intrapulmonary drug delivery within therapeutically relevant inspiratory flow/volume values |
| US5522385A (en) | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
| US5766582A (en) * | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
| US5906202A (en) | 1996-11-21 | 1999-05-25 | Aradigm Corporation | Device and method for directing aerosolized mist to a specific area of the respiratory tract |
| US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
| KR100399156B1 (ko) * | 1999-11-19 | 2003-09-26 | 주식회사 엘지생명과학 | α-인터페론의 용액제형 |
| CZ20022220A3 (cs) | 1999-12-30 | 2003-01-15 | Intermune, Inc. | Aerosol s kapkami kapaliny gama-IFN a jeho pouľití |
| US6875748B2 (en) * | 2000-04-21 | 2005-04-05 | Vical Incorporated | Compositions and methods for in vivo delivery of polynucleotide-based therapeutics |
| IN191090B (enExample) * | 2000-08-29 | 2003-09-20 | Ranbanx Lab Ltd | |
| WO2002036072A2 (en) * | 2000-11-03 | 2002-05-10 | Biomedicines, Inc. | Method for short-term and long-term drug dosimetry |
-
2002
- 2002-05-31 US US10/159,083 patent/US6830744B2/en not_active Expired - Fee Related
-
2003
- 2003-04-08 AU AU2003221700A patent/AU2003221700A1/en not_active Abandoned
- 2003-04-08 JP JP2004509705A patent/JP2005531604A/ja active Pending
- 2003-04-08 EP EP03718279A patent/EP1515744A4/en not_active Withdrawn
- 2003-04-08 WO PCT/US2003/010832 patent/WO2003102014A2/en not_active Ceased
- 2003-04-08 CA CA002484626A patent/CA2484626A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003102014A2 (en) | 2003-12-11 |
| JP2005531604A (ja) | 2005-10-20 |
| EP1515744A2 (en) | 2005-03-23 |
| WO2003102014A3 (en) | 2004-09-30 |
| AU2003221700A1 (en) | 2003-12-19 |
| US20030223936A1 (en) | 2003-12-04 |
| EP1515744A4 (en) | 2008-04-16 |
| US6830744B2 (en) | 2004-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5580521B2 (ja) | インターフェロン−βのＨＳＡ非含有処方物 | |
| EP2076242B1 (en) | Aerosolizable formulation comprising insulin for pulmonary delivery | |
| KR102465025B1 (ko) | 열-안정성 건조 분말 약제학적 조성물 및 방법 | |
| JP4195191B2 (ja) | エーロゾル化されたアクティブ・エージェントの投与 | |
| US20050203002A1 (en) | Sustained release compositions for delivery of pharmaceutical proteins | |
| US20110268668A1 (en) | Process for nebulizing aqueous compositions containing highly concentrated insulin | |
| US20030064032A1 (en) | Process for nebulizing aqueous compositions containing highly concentrated insulin | |
| CZ2001690A3 (cs) | Způsob podávání inzulinotropních peptidů | |
| US20050232899A1 (en) | Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b | |
| US6830744B2 (en) | Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b | |
| WO2001087278A1 (en) | Insulin formulation for inhalation | |
| CN116785265A (zh) | 一种高效广谱的抗冠状病毒多肽的吸入制剂及其制备方法 | |
| JP2005531604A5 (enExample) | ||
| JPH05500229A (ja) | 固体ポリペプチド微粒子のエアロゾル製剤とその製造方法 | |
| US20250312419A1 (en) | Pharmaceutical compositions and methods | |
| Clark et al. | Formulation of proteins for pulmonary delivery | |
| US20220323546A1 (en) | Recombinant interferon | |
| Clark | Dry powder inhalation systems from inhale therapeutic systems | |
| HK1033438A (en) | Aerosolized active agent delivery | |
| MXPA00008994A (en) | Aerosolized active agent delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 20120620 |